ACR Applauds Initiatives to Speed FDA Biosimilar Approvals
American College of Rheumatology (ACR)“Expanding our patients’ access to safe, effective, and affordable biologic and biosimilar therapies is a top priority of the rheumatology community. Therefore, the American College of Rheumatology applauds new legislative and regulatory developments that will expedite the approval of new therapies, increase competition, and lower the cost of these drugs.